- Home
- DOW vs GMAB Comparison
DOW vs GMAB Comparison
Compare DOW & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOW
- GMAB
- Stock Information
- Founded
- DOW 1897
- GMAB 1999
- Country
- DOW United States
- GMAB Denmark
- Employees
- DOW N/A
- GMAB N/A
- Industry
- DOW Major Chemicals
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- DOW Industrials
- GMAB Health Care
- Exchange
- DOW Nasdaq
- GMAB Nasdaq
- Market Cap
- DOW 16.3B
- GMAB 17.4B
- IPO Year
- DOW N/A
- GMAB N/A
- Fundamental
- Price
- DOW $22.05
- GMAB $31.70
- Analyst Decision
- DOW Hold
- GMAB Strong Buy
- Analyst Count
- DOW 15
- GMAB 7
- Target Price
- DOW $28.13
- GMAB $41.17
- AVG Volume (30 Days)
- DOW 13.5M
- GMAB 2.3M
- Earning Date
- DOW 10-23-2025
- GMAB 11-05-2025
- Dividend Yield
- DOW 6.34%
- GMAB N/A
- EPS Growth
- DOW N/A
- GMAB 77.72
- EPS
- DOW N/A
- GMAB 21.62
- Revenue
- DOW $41,819,000,000.00
- GMAB $3,646,881,232.00
- Revenue This Year
- DOW N/A
- GMAB $24.25
- Revenue Next Year
- DOW $2.95
- GMAB $16.29
- P/E Ratio
- DOW N/A
- GMAB $14.35
- Revenue Growth
- DOW N/A
- GMAB 32.97
- 52 Week Low
- DOW $20.40
- GMAB $17.24
- 52 Week High
- DOW $54.17
- GMAB $33.63
- Technical
- Relative Strength Index (RSI)
- DOW 36.20
- GMAB 68.13
- Support Level
- DOW $22.25
- GMAB $28.36
- Resistance Level
- DOW $24.04
- GMAB $33.63
- Average True Range (ATR)
- DOW 0.71
- GMAB 0.64
- MACD
- DOW -0.07
- GMAB 0.08
- Stochastic Oscillator
- DOW 4.04
- GMAB 64.52
About DOW Dow Inc.
Dow Chemical is a diversified global chemicals producer, formed in 2019 as a result of the DowDuPont merger and subsequent separations. The firm is a leading producer of several chemicals, including polyethylene, ethylene oxide, and silicone rubber. Its products have numerous applications in both consumer and industrial end markets.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.